.png){kind=icon}
.png){kind=icon}
Return
Current Applications and Development of Dual-Target Inhibitors of IDO1/TDO: From Tumor Immunology to Neuropsychiatric Disorders
.png){kind=icon}
PRE
AI
W
J
L
K
J
江
DOI：10.1016/j.ejmech.2026.118946.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• IDO-1 and TDO are rate-limiting enzymes in the kynurenine pathway linking immunity and neurology • Single-target IDO-1 inhibitors face clinical setbacks due to TDO compensation and tumor heterogeneity • Dual IDO-1/TDO inhibitors offer a strategic advantage to block metabolic immune escape comprehensively • Key scaffolds include β-carboline, indazole, indole, isoquinoline, and natural product-derived chemotypes • Dual IDO1-TDO inhibitors bridge cancer immunotherapy and neuropsychiatric disorder treatment.
Keywords:
IDO-1
TDO
dual inhibitors
kynurenine pathway
cancer immunotherapy
Journal
IF:
5.9
Papers:
1.7W
Citations:
6.0W
Organization
No organization information available
Cited Papers